Background: We previously reported that a median of 5.6 years of intensive as compared with standard glucose lowering in 1791 military veterans with type 2 diabetes resulted in a risk of major cardiovascular events that was significantly lower (by 17%) after a total of 10 years of combined intervention and observational follow-up.
Phase III BEST trial data shows that THR 1442 (bexagliflozin) from Theracos, lowers weight, blood pressure and glycated haemoglobin (HbA1c) relative to placebo in patients with type 2 diabetes at high risk for cardiovascular (CV) events.
Abbott announced results from a new meta-analysis of 75 real-world, observational studies demonstrating that its FreeStyle Libre system provides significant reductions in glycated haemoglobin (HbA1c) that are sustained over up to 24 months in adults with both type 1 and type 2 diabetes.
This guideline covers assessing and managing oesophago-gastric cancer in adults, including radical and palliative treatment and nutritional support.
This study aimed to examine the most reliable evidence on the relationship between early menopause and the risk of heart failure and atrial fibrillation.
This guideline covers managing stable angina in people aged 18 and over. It outlines the importance of addressing the person’s concerns about stable angina and the roles of medical therapy and revascularisation.
This guideline covers the developmental follow-up of babies, children and young people under 18 years who were born preterm (before 37+0 weeks of pregnancy).
This guideline covers identifying and caring for adults who are malnourished or at risk of malnutrition in hospital or in their own home or a care home.
This guideline covers rehabilitation strategies for adults who have experienced a critical illness and stayed in critical care.
This guideline is restricted to GI endoscopy but we cover elective and acute or emergency procedures.